DOAC dosing guided by the Cockcroft-Gault formula had an approximately 94% concordance rate with CKD-EPI and MDRD formulae, and on-label use was associated with lower major bleeding than warfarin.
Cohort (n=6,268)
Do different renal function estimation formulae (CKD-EPI, MDRD vs CG) for dosing DOACs alter the risks of thromboembolism and major bleeding in patients with atrial fibrillation?
Although the Cockcroft-Gault formula underestimates renal function in underweight and elderly patients compared to non-CG formulae, clinical outcomes of thromboembolism and major bleeding remain similar regardless of the formula used for DOAC dosing.
The Cockcroft-Gault (CG) formula is recommended to guide clinicians in the choice of the appropriate dosage for direct oral anticoagulants (DOACs). However, the performance of the CG formula varies depending on the patient's age, weight, and degree of renal function. We aimed to compare the validity of the CG formula with that of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) formulae for dosing DOACs. A total of 6268 consecutive patients on anticoagulants for atrial fibrillation (AF) were retrospectively investigated. Among underweight and elderly patients, the CG formula underestimated renal function compared with the non-CG formulae. However, the concordant rate of drug indications between the CG and the non-CG formulae was approximately 94%. On-label uses under the three formulae were associated with a lower risk of major bleeding (but not thromboembolism) compared to warfarin. Although we found differences in estimating renal function and the proportions of drug indications between the CG and non-CG formulae, the risks of thromboembolism and major bleeding were similar to those with warfarin regardless of which formula was used.
Lee et al. (Thu,) conducted a cohort in Atrial Fibrillation (n=6,268). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Thromboembolism and major bleeding. DOAC dosing guided by the Cockcroft-Gault formula had an approximately 94% concordance rate with CKD-EPI and MDRD formulae, and on-label use was associated with lower major bleeding than warfarin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: